Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis

Low-Dose of Intrapulmonary Pirfenidone Improves Human Transforming Growth Factorβ1-Driven Lung Fibrosis

Idiopathic pulmonary fibrosis is a chronic, progressive, and lethal lung disease of unknown etiology. Antifibrotic drugs, including pirfenidone, are currently used for the treatment of the disease. The oral administration of pirfenidone is an effective therapy, as demonstrated by several clinical tr...

Full description

Bibliographic Details
Main Authors: Tomohito Okano, Tetsu Kobayashi, Taro Yasuma, Corina N. D’Alessandro-Gabazza, Masaaki Toda, Hajime Fujimoto, Hiroki Nakahara, Yuko Okano, Atsuro Takeshita, Kota Nishihama, Haruko Saiki, Atsushi Tomaru, Valeria Fridman D’Alessandro, Satoru Ishida, Hiromi Sugimoto, Yoshiyuki Takei, Esteban C. Gabazza
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-11-01
Series:Frontiers in Pharmacology
Subjects:
idiopathic pulmonary fibrosis
pirfenidone
intrapulmonary delivery
oral therapy
adverse effects
drug delivery
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2020.593620/full

Similar Items

Similar Items